Symbols / CVKD Stock $5.06 -4.08% Cadrenal Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
CVKD (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Quang X. Pham
Exch · Country NCM · United States
Market Cap 15.56M
Enterprise Value 11.08M
Income -13.24M
Sales —
FCF (ttm) -7.78M
Book/sh 1.17
Cash/sh 1.60
Employees —
Insider 10d —
IPO Jan 20, 2023
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.29
PEG —
P/S —
P/B 4.32
P/C —
EV/EBITDA -0.82
EV/Sales —
Quick Ratio 2.53
Current Ratio 2.72
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -5.59
EPS next Y -3.91
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-05-07
ROA -116.44%
ROE -260.11%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 3.08M
Shs Float 2.08M
Insider Own 16.99%
Instit Own 6.09%
Short Float 1.66%
Short Ratio 1.01
Short Interest 43.51K
52W High 15.99
vs 52W High -68.39%
52W Low 4.21
vs 52W Low 20.07%
Beta 1.83
Impl. Vol. —
Rel Volume 0.83
Avg Volume 57.42K
Volume 47.76K
Target (mean) $27.67
Tgt Median $25.00
Tgt Low $13.00
Tgt High $45.00
# Analysts 3
Recom Strong_buy
Prev Close $5.27
Price $5.05
Change -4.08%
About

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$27.67
Mean price target
2. Current target
$5.06
Latest analyst target
3. DCF / Fair value
$-45.52
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.06
Low
$13.00
High
$45.00
Mean
$27.67

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-07 main HC Wainwright & Co. Buy → Buy $13
2025-05-16 reit HC Wainwright & Co. Buy → Buy $32
2024-11-11 main HC Wainwright & Co. Buy → Buy $32
2024-06-06 reit HC Wainwright & Co. Buy → Buy $3
2024-05-09 reit HC Wainwright & Co. Buy → Buy $3
2024-03-14 reit HC Wainwright & Co. Buy → Buy $3
2023-12-18 init Noble Capital Markets — → Outperform $4
2023-11-20 init HC Wainwright & Co. — → Buy $3
News
RSS: Latest CVKD news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-12-29 SZOT MATTHEW K Chief Financial Officer — 9,933 $6.97 $69,233
2025-10-27 SZOT MATTHEW K Chief Financial Officer — 3,600 $13.99 $50,364
2025-10-27 PHAM QUANG X Chief Executive Officer — 2,444 $13.99 $34,237
2025-10-13 SZOT MATTHEW K Chief Financial Officer — 3,493 $13.99 $49,011
2025-10-13 PHAM QUANG X Chief Executive Officer — 3,600 $14.02 $50,706
2025-10-06 SZOT MATTHEW K Chief Financial Officer — 107 $13.99 $1,497
2025-10-02 PHAM QUANG X Chief Executive Officer — 500 $14.13 $7,065
2025-10-01 SZOT MATTHEW K Chief Financial Officer — 1,800 $13.99 $25,183
2025-10-01 PHAM QUANG X Chief Executive Officer — 1,300 $14.01 $18,213
2025-09-25 SZOT MATTHEW K Chief Financial Officer — 12,400 $14.00 $174,175
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Total Revenue
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
Operating Expense
13.46
+22.81%
10.96
+43.60%
7.63
Research And Development
4.10
-2.49%
4.21
+3.03%
4.08
Selling General And Administration
9.35
+38.50%
6.75
+90.27%
3.55
General And Administrative Expense
9.35
+38.50%
6.75
+90.27%
3.55
Other Gand A
9.35
+38.50%
6.75
+90.27%
3.55
Total Expenses
13.46
+22.81%
10.96
+43.60%
7.63
Operating Income
-13.46
-22.81%
-10.96
-43.60%
-7.63
Total Operating Income As Reported
-13.46
-22.81%
-10.96
-43.60%
-7.63
EBITDA
-13.45
-22.77%
-10.96
-31.43%
-8.34
Normalized EBITDA
-13.45
-22.77%
-10.96
-48.46%
-7.38
Reconciled Depreciation
0.01
+265.64%
0.00
-5.05%
0.00
EBIT
-13.46
-22.81%
-10.96
-31.42%
-8.34
Total Unusual Items
—
0.00
+100.00%
-0.96
Total Unusual Items Excluding Goodwill
—
0.00
+100.00%
-0.96
Special Income Charges
—
0.00
+100.00%
-0.74
Other Special Charges
—
—
0.74
Net Income
-13.24
-24.28%
-10.65
-27.45%
-8.36
Pretax Income
-13.24
-24.28%
-10.65
-27.45%
-8.36
Net Non Operating Interest Income Expense
0.22
-27.63%
0.31
+33.30%
0.23
Interest Expense Non Operating
—
0.00
-100.00%
0.02
Net Interest Income
0.22
-27.63%
0.31
+33.30%
0.23
Interest Expense
—
0.00
-100.00%
0.02
Interest Income Non Operating
0.22
-27.63%
0.31
+24.15%
0.25
Interest Income
0.22
-27.63%
0.31
+24.15%
0.25
Other Income Expense
—
—
-0.96
Gain On Sale Of Security
—
—
-0.22
Tax Rate For Calcs
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-13.24
-24.28%
-10.65
-27.45%
-8.36
Net Income From Continuing Operation Net Minority Interest
-13.24
-24.28%
-10.65
-27.45%
-8.36
Net Income From Continuing And Discontinued Operation
-13.24
-24.28%
-10.65
-27.45%
-8.36
Net Income Continuous Operations
-13.24
-24.28%
-10.65
-27.45%
-8.36
Normalized Income
-13.24
-24.28%
-10.65
-43.92%
-7.40
Net Income Common Stockholders
-13.24
-24.28%
-10.65
-27.45%
-8.36
Diluted EPS
—
-8.73
+6.03%
-9.29
Basic EPS
—
-8.73
+6.03%
-9.29
Basic Average Shares
—
1.22
+35.59%
0.90
Diluted Average Shares
—
1.22
+35.59%
0.90
Diluted NI Availto Com Stockholders
-13.24
-24.28%
-10.65
-27.45%
-8.36
Depreciation Amortization Depletion Income Statement
0.01
+265.64%
0.00
-5.05%
0.00
Depreciation And Amortization In Income Statement
0.01
+265.64%
0.00
-5.05%
0.00
Depreciation Income Statement
0.01
+265.64%
0.00
-5.05%
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
4.33
-57.26%
10.12
+18.83%
8.52
+994.77%
0.78
Current Assets
4.32
-57.29%
10.11
+19.08%
8.49
+1067.15%
0.73
Cash Cash Equivalents And Short Term Investments
4.01
-59.99%
10.02
+19.23%
8.40
+25685.61%
0.03
Cash And Cash Equivalents
4.01
-59.99%
10.02
+19.23%
8.40
+25685.61%
0.03
Cash Financial
—
—
—
0.03
Receivables
0.01
-86.64%
0.04
+2.43%
0.04
—
Accrued Interest Receivable
0.01
-86.64%
0.04
+2.43%
0.04
—
Prepaid Assets
—
0.04
-19.40%
0.05
+130.79%
0.02
Current Deferred Assets
0.11
+636.19%
0.01
0.00
-100.00%
0.67
Other Current Assets
0.20
+373.63%
0.04
-19.40%
0.05
+130.79%
0.02
Total Non Current Assets
0.01
-31.62%
0.01
-60.35%
0.03
-46.46%
0.05
Net PPE
0.01
-25.49%
0.01
-70.18%
0.02
-47.78%
0.04
Gross PPE
0.01
-25.49%
0.01
-70.18%
0.02
-47.78%
0.04
Other Properties
0.01
-25.49%
0.01
-70.18%
0.02
-47.78%
0.04
Other Non Current Assets
0.00
-42.85%
0.00
+0.00%
0.00
-36.66%
0.01
Total Liabilities Net Minority Interest
1.59
-40.83%
2.68
+224.59%
0.83
-86.94%
6.33
Current Liabilities
1.59
-40.83%
2.68
+224.59%
0.83
-38.04%
1.33
Payables And Accrued Expenses
0.85
-50.23%
1.72
+720.17%
0.21
-68.43%
0.66
Payables
0.65
-56.69%
1.50
+797.97%
0.17
-58.68%
0.40
Accounts Payable
0.65
-56.69%
1.50
+797.97%
0.17
-58.68%
0.40
Current Accrued Expenses
0.20
-5.02%
0.21
+410.79%
0.04
-83.71%
0.26
Pensionand Other Post Retirement Benefit Plans Current
0.73
-24.14%
0.97
+62.14%
0.60
-1.51%
0.61
Current Debt And Capital Lease Obligation
—
—
0.02
-67.66%
0.07
Current Debt
—
—
—
0.04
Current Capital Lease Obligation
—
0.00
-100.00%
0.02
-4.21%
0.02
Total Non Current Liabilities Net Minority Interest
0.00
0.00
0.00
-100.00%
4.99
Long Term Debt And Capital Lease Obligation
—
—
0.00
-100.00%
0.57
Long Term Debt
—
—
—
0.55
Long Term Capital Lease Obligation
—
—
0.00
-100.00%
0.02
Stockholders Equity
2.74
-63.19%
7.44
-3.29%
7.69
+238.57%
-5.55
Common Stock Equity
2.74
-63.19%
7.44
-3.29%
7.69
+238.57%
-5.55
Capital Stock
0.00
+31.20%
0.00
+105.30%
0.00
-89.41%
0.01
Common Stock
0.00
+31.20%
0.00
+105.30%
0.00
-89.41%
0.01
Preferred Stock
0.00
0.00
0.00
—
Share Issued
2.34
+31.17%
1.78
+105.31%
0.87
+11.93%
0.78
Ordinary Shares Number
2.34
+31.17%
1.78
+105.31%
0.87
+11.93%
0.78
Additional Paid In Capital
41.70
+25.74%
33.16
+45.68%
22.76
+1870.84%
1.15
Retained Earnings
-38.96
-51.46%
-25.72
-70.67%
-15.07
-124.47%
-6.71
Total Equity Gross Minority Interest
2.74
-63.19%
7.44
-3.29%
7.69
+238.57%
-5.55
Total Capitalization
2.74
-63.19%
7.44
-3.29%
7.69
+253.91%
-5.00
Working Capital
2.73
-63.23%
7.43
-3.08%
7.67
+1363.06%
-0.61
Invested Capital
2.74
-63.19%
7.44
-3.29%
7.69
+255.27%
-4.95
Total Debt
—
0.00
-100.00%
0.02
-96.67%
0.64
Net Debt
—
—
—
0.56
Capital Lease Obligations
—
0.00
-100.00%
0.02
-51.07%
0.04
Net Tangible Assets
2.74
-63.19%
7.44
-3.29%
7.69
+238.57%
-5.55
Tangible Book Value
2.74
-63.19%
7.44
-3.29%
7.69
+238.57%
-5.55
Current Notes Payable
—
—
0.00
-100.00%
0.04
Derivative Product Liabilities
—
—
0.00
-100.00%
4.38
Non Current Accrued Expenses
—
—
0.00
-100.00%
0.04
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Operating Cash Flow
-12.60
-71.28%
-7.36
-108.41%
-3.53
Cash Flow From Continuing Operating Activities
-12.60
-71.28%
-7.36
-108.41%
-3.53
Net Income From Continuing Operations
-13.24
-24.28%
-10.65
-27.45%
-8.36
Depreciation Amortization Depletion
0.01
+265.64%
0.00
-5.05%
0.00
Depreciation
0.01
+265.64%
0.00
-5.05%
0.00
Depreciation And Amortization
0.01
+265.64%
0.00
-5.05%
0.00
Other Non Cash Items
—
-0.00
-100.01%
3.01
Stock Based Compensation
1.94
+36.70%
1.42
+99.76%
0.71
Operating Gains Losses
—
—
0.96
Gain Loss On Investment Securities
—
—
0.22
Change In Working Capital
-1.31
-169.99%
1.87
+1198.08%
0.14
Change In Receivables
0.03
+3752.71%
-0.00
+97.57%
-0.04
Change In Prepaid Assets
-0.16
-1652.74%
0.01
+134.22%
-0.03
Change In Payables And Accrued Expense
-1.10
-158.35%
1.88
+505.51%
-0.46
Change In Accrued Expense
-0.24
-144.94%
0.54
+340.77%
-0.23
Change In Payable
-0.85
-163.80%
1.34
+661.98%
-0.24
Change In Account Payable
-0.85
-163.80%
1.34
+661.98%
-0.24
Change In Other Working Capital
-0.09
-536.19%
-0.01
-102.15%
0.67
Change In Other Current Assets
0.00
0.00
-100.00%
0.00
Investing Cash Flow
-0.01
+21.92%
-0.01
-100.89%
-0.00
Cash Flow From Continuing Investing Activities
-0.01
+21.92%
-0.01
-100.89%
-0.00
Net PPE Purchase And Sale
-0.01
+21.92%
-0.01
-100.89%
-0.00
Purchase Of PPE
-0.01
+21.92%
-0.01
-100.89%
-0.00
Capital Expenditure
-0.01
+21.92%
-0.01
-100.89%
-0.00
Financing Cash Flow
6.60
-26.54%
8.98
-24.56%
11.90
Cash Flow From Continuing Financing Activities
6.60
-26.54%
8.98
-24.56%
11.90
Net Issuance Payments Of Debt
—
0.00
+100.00%
-0.25
Issuance Of Debt
—
—
0.00
Repayment Of Debt
—
0.00
+100.00%
-0.25
Long Term Debt Issuance
—
—
0.00
Net Long Term Debt Issuance
—
—
0.00
Short Term Debt Payments
—
0.00
+100.00%
-0.25
Net Short Term Debt Issuance
—
0.00
+100.00%
-0.25
Net Common Stock Issuance
6.87
+33.52%
5.14
-56.79%
11.90
Common Stock Payments
-0.29
0.00
—
Repurchase Of Capital Stock
-0.29
0.00
—
Proceeds From Stock Option Exercised
0.00
-100.00%
4.71
+1785.84%
0.25
Net Other Financing Charges
-0.27
+69.13%
-0.88
—
Changes In Cash
-6.01
-472.04%
1.62
-80.70%
8.37
Beginning Cash Position
10.02
+19.23%
8.40
+25685.61%
0.03
End Cash Position
4.01
-59.99%
10.02
+19.23%
8.40
Free Cash Flow
-12.61
-71.19%
-7.36
-108.40%
-3.53
Change In Interest Payable
—
—
0.00
Common Stock Issuance
7.16
+39.20%
5.14
-56.79%
11.90
Issuance Of Capital Stock
7.16
+39.20%
5.14
-56.79%
11.90
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category